Friday, May 25, 2012 3:53:25 PM
Rosetta Genomics: Study validating miRview mets2 published in The Oncologist says 'vast majority of samples resulting in a single reported origin, which was accurate in 90% of the cases' (ROSG) 15.48 -0.81 : The article provides an in-depth description of the test, its development and its mechanism of action. In the study, the assay was first validated on 509 samples of known origin in a blinded manner and demonstrated 85% accuracy, with the vast majority of samples resulting in a single reported origin, which was accurate in 90% of the cases. The study then extended the validation to CUP, which is the most difficult diagnostic challenge for a test designed to identify tumor origin. The investigators performed validation of the assay on CUP cases, assessing the performance of the assay using clinico-pathologic evaluation, and demonstrated that the performance of the assay remains the same for these challenging cases. This high level of accuracy in identifying the tumor-of-origin were similar to the 92% concordance demonstrated in a study conducted in Greece and recently presented at the United States and Canadian Academy of Pathology.
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM